ArticleJournal of thoracic disease2018

Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer.

Minoru Fukuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.